Department of Quality of Life, European Organisation for Research and Treatment of Cancer Headquarters (EORTC HQ), Brussels, Belgium.
Ann Oncol. 2013 Jan;24(1):231-7. doi: 10.1093/annonc/mds220. Epub 2012 Aug 30.
We examined if cancer patients' health-related quality of life (HRQoL) scores on the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 are affected by the specific time point, before or during treatment, at which the questionnaire is completed, and whether this could bias the overall treatment comparison analyses.
A 'completion-time window' variable was created on three closed EORTC randomised control trials in lung (non-small cell lung cancer, NSCLC) and colorectal cancer (CRC) to indicate when the QLQ-30 was completed relative to chemotherapy cycle dates, defined as 'before', 'on' and 'after'. HRQoL mean scores were calculated using a linear mixed model.
Statistically significant differences (P<0.05) were observed on 6 and 5 scales for 'on' and 'after' comparisons in the NSCLC and two-group CRC trial, respectively. As for the three-group CRC trial, several statistical differences were observed in the 'before' to 'on' and the 'on' to 'after' comparisons. For all three trials, including the 'completion-time window' variable in the model resulted in a better fit, but no substantial changes in the treatment effects were noted.
We showed that considering the exact timing of completion within specified windows resulted in statistical and potentially clinically significant differences, but it did not alter the conclusions of treatment comparison in these studies.
我们研究了癌症患者在欧洲癌症研究与治疗组织(EORTC)QLQ-C30 上的健康相关生活质量(HRQoL)评分是否受到完成问卷的特定时间点(治疗前或治疗期间)的影响,以及这是否会影响总体治疗比较分析。
我们在三个关于肺癌(非小细胞肺癌,NSCLC)和结直肠癌(CRC)的 EORTC 随机对照试验中创建了一个“完成时间窗”变量,以指示 QLQ-30 相对于化疗周期日期的完成时间,定义为“之前”、“期间”和“之后”。使用线性混合模型计算 HRQoL 平均得分。
在 NSCLC 和两组 CRC 试验中,“期间”和“之后”比较的 6 个和 5 个量表上观察到统计学显著差异(P<0.05)。对于三组 CRC 试验,在“之前”到“期间”和“期间”到“之后”的比较中观察到了几个统计学差异。对于所有三个试验,在模型中包含“完成时间窗”变量导致了更好的拟合,但治疗效果没有实质性变化。
我们表明,考虑到特定时间窗内的确切完成时间会导致统计学和潜在临床显著差异,但这并未改变这些研究中治疗比较的结论。